From the publishers of JADPRO

DLBCL Resource Center


Targeted therapies shake up the DLBCL treatment paradigm, expert says

This review provides an overview of the current standard of care for DLBCL, including R-CHOP and the newly approved polatuzumab vedotin, as well as emerging treatment options and associated clinical trial data.

News & Literature Highlights

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management


Treatment resistance in diffuse large B-cell lymphoma

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study


Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma


Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Journal of Clinical Oncology

Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective Elderly Project of the Fondazione Italiana Linfomi

British Journal of Haematology

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Journal of Clinical Oncology

Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial